Oribel Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$54.3M |
| 2 |
Agilent Technologies
A
|
+$51.5M |
| 3 |
Salesforce
CRM
|
+$42.8M |
| 4 |
Intercontinental Exchange
ICE
|
+$39.1M |
| 5 |
Equifax
EFX
|
+$36.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Synopsys
SNPS
|
+$72.7M |
| 2 |
Icon
ICLR
|
+$40.6M |
| 3 |
Broadcom
AVGO
|
+$37.5M |
| 4 |
WCN
Waste Connections
WCN
|
+$32.2M |
| 5 |
Adobe
ADBE
|
+$28.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.03% |
| 2 | Healthcare | 9.8% |
| 3 | Financials | 7.37% |
| 4 | Industrials | 6.65% |
| 5 | Consumer Discretionary | 2.82% |
Similar funds
Oribel Capital Management's Q4 2023 Portfolio in Review
As of Q4 2023, Oribel Capital Management held 115 positions worth $1.51B, up 33% from $1.13B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Oribel Capital Management deployed $240M of net new capital in Q4 2023, opening 46 new positions and adding to 11 existing holdings. Its largest new stake was Thermo Fisher Scientific: 112,200 shares worth $59.6M.
By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 33% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Icon, an estimated $40.6M trimmed.
- Oribel Capital Management's largest Q4 2023 buy was Thermo Fisher Scientific: 112,200 shares worth $59.6M.
- Oribel Capital Management added most to Microsoft in Q4 2023, an estimated $21M increase.
- Oribel Capital Management's biggest Q4 2023 reduction was Icon, cutting an estimated $40.6M.
- Oribel Capital Management fully exited Synopsys in Q4 2023, selling an estimated $72.7M.
- Oribel Capital Management's ten largest holdings make up 35% of its $1.51B portfolio in Q4 2023.
- Oribel Capital Management opened 46 new positions and closed 47 in Q4 2023.
- Oribel Capital Management's portfolio value rose 33% quarter-over-quarter to $1.51B.
Based on Oribel Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.